Inogen
INGN
Market cap $185M

7.13 USD

-0.15

2.06%

At close Apr 30, 4:00 PM EDT

After hours

7.13

+0.00

0.00%

1 day

-2.06%

5 days

3.18%

1 month

0.00%

3 months

-40.33%

6 months

-23.09%

Year to date

-22.42%

1 year

4.85%

5 years

-85.74%

10 years

-80.59%

About: Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

Employees: 766

Healthcare Medical Devices

0

Funds holding %

of 7,425 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

115% more call options, than puts

Call options by funds: $2.11M | Put options by funds: $979K

67% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 30

20% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 20

1% more funds holding

Funds holding: 133 [Q3] → 134 (+1) [Q4]

1.37% less ownership

Funds ownership: 85.45% [Q3] → 84.08% (-1.37%) [Q4]

7% less capital invested

Capital invested by funds: $197M [Q3] → $184M (-$12.9M) [Q4]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for INGN.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

Inogen To Present at 24th Annual Needham Virtual Healthcare Conference

GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen To Present at 24th Annual Needham Virtual Healthcare Conference.

Inogen To Present at 24th Annual Needham Virtual Healthcare Conference

Zacks Investment Research

Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid fourth-quarter 2024 performance and a strong product portfolio, seems justified.

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

A Volatile Share Price Masks Some Of The Progress At Inogen

Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage.

A Volatile Share Price Masks Some Of The Progress At Inogen

What's Going On With MedTech Focused Inogen Stock On Wednesday?

Medical Technology company Inogen Inc INGN reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the consensus loss of 61 cents.

What's Going On With MedTech Focused Inogen Stock On Wednesday?

Zacks Investment Research

INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up

Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales.

INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up

Inogen, Inc. (INGN) Q4 2024 Earnings Call Transcript

Inogen, Inc. (NASDAQ:INGN ) Q4 2024 Earnings Conference Call February 25, 2025 5:00 PM ET Company Participants Ryan Peterson – Investor Relations Kevin Smith – President and Chief Executive Officer Mike Bourque – Chief Financial Officer Conference Call Participants Operator Welcome to Inogen's Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Inogen, Inc. (INGN) Q4 2024 Earnings Call Transcript

Zacks Investment Research

Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates

Inogen (INGN) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $1.14 per share a year ago.

Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates

Inogen Announces Fourth Quarter and Full Year 2024 Financial Results

GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter and the full year ended December 31, 2024. “2024 was a stellar year for Inogen. With our new leadership team in place, we returned the Company to growth, achieved significant milestones, and made meaningful steps towards profitability,” said Kevin Smith, President and Chief Executive.

Inogen Announces Fourth Quarter and Full Year 2024 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™